Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

BackgroundFluid biomarkers enable the demonstration of the biological effects of novel therapies in Alzheimers disease (AD). However, longitudinal biomarker data are sparse and sample size calculations for fluid biomarkers are often lacking. Here, we provided longitudinal CSF and plasma AD biomarkers measured in samples collected in a placebo arm in a 1.5-year phase 2b trial, allowing us to study natural trajectories, required sample sizes and heterogeneity in early AD clinical trials. MethodsWe studied individuals from the placebo group (MCI due to AD (n=65) and AD dementia (n=41)) of the T-817MA trial (NCT04191486) with positive CSF AD biomarkers (mean age=69{+/-}7 years, Female=63%). Longitudinal biomarker changes in CSF (A{beta}42, A{beta}40, A{beta}42/40, pTau181, pTau217, NFL, tTau, YKL40, NRGN, ABL1, CHIT1, CLEC5A, ITGB2, MMP10, SDC4, SPON2, THBD) and plasma biomarkers (A{beta}42, A{beta}40, A{beta}42/40, pTau181, pTau217, NFL, GFAP) were analyzed with linear mixed-effect models. Required sample size estimates for predefined treatment effects were generated. Lastly, we investigated the influence of between person variability in biomarker change by simulating a randomized clinical trial (1:1) 10000 times, and assessed the group differences at 1.5 years. FindingsFourteen biomarkers changed over time, with the largest annual changes observed for plasma pTau217 (+9.8%), CSF MMP10 (+7.1%), and CSF NFL (+6.9%), and CSF A{beta}40 by (-4.0%), CSF pTau217 (-3.0%), and CSF NRGN (-2.5%). To show a 30% change, similar to biomarker effects of approved AD drugs, almost all markers required less than 45 patients per trial arm. To reach normalized levels, established CSF markers required lower sample sizes than plasma markers. The effects of heterogeneity over time were approximately twice as large in plasma compared to CSF. InterpretationThese findings offer insights into the biomarker trajectories and power in early AD, supporting more informed endpoint selection and forming a frame of reference for the interpretation of treatment effects in clinical trials.

What this study adds

Evidence grade: High

This is a follow-up (cohort) study of 65 participants. Using placebo-arm data from a phase 2b trial, this study described longitudinal fluid biomarker trajectories in early Alzheimer's disease and estimated sample sizes needed for trials, finding that heterogeneity over time was about twice as large in plasma as in CSF. Reported effect size: 9.8%; 7.1%; 6.9%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Oosthoek, M., Leistra, A., Hok-A-Hin, Y. S., Tanck, M. W. T., Okuda, T., in 't Veld, L., et al. (2026). Treatment response biomarkers in early Alzheimers disease: longitudinal trajectories, sample size estimates, and the impact of progression variability. medRxiv (preprint). https://doi.org/10.64898/2026.08.27.26361425

Vancouver

Oosthoek M, Leistra A, Hok-A-Hin YS, Tanck MWT, Okuda T, in 't Veld L, et al. Treatment response biomarkers in early Alzheimers disease: longitudinal trajectories, sample size estimates, and the impact of progression variability. medRxiv (preprint). 2026. doi:10.64898/2026.08.27.26361425.

BibTeX

@article{oosthoek2026-59d29669,
  author  = {Oosthoek, M. and Leistra, A. and Hok-A-Hin, Y. S. and Tanck, M. W. T. and Okuda, T. and in 't Veld, L. and Aladdin, A. and Bokhoven, van and others},
  title   = {{Treatment response biomarkers in early Alzheimers disease: longitudinal trajectories, sample size estimates, and the impact of progression variability}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.08.27.26361425},
  url     = {https://doi.org/10.64898/2026.08.27.26361425}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Using placebo-arm data from a phase 2b trial, this study described longitudinal fluid biomarker trajectories in early Alzheimer's disease and estimated sample sizes needed for trials, finding that heterogeneity over time was about twice as large in plasma as in CSF. It is about trial design and biomarker measurement, not treating, curing or preventing the disease.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 5 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 37 of the 94 points it could be judged on, which is 39 of 100. Raw total 39 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 39 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 39 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 37 of the 94 points we could judge it on, which is 39 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 1 / 4 65 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Lisa Vermunt: h-index 26 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Amsterdam: institution h-index 1,209 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 37 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 94 points we could judge it on is 39 out of 100.
Total 39 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →